期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 85, 期 3, 页码 315-331出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2012.09.009
关键词
Paclitaxel albumin; Taxane; Breast cancer; Metastatic; SPARC; Biomarkers
资金
- Celgene Corporation
- Sanofi-Aventis
- Celgene International Sarl
The first-generation taxanes, conventional paclitaxel and docetaxel, are established treatment options for adjuvant and metastatic breast cancer (MBC). However, these agents have limitations, including primary/secondary resistance and harsh toxicities. The introduction of paclitaxel albumin represents a significant advance in taxane therapy as the first of a new generation of taxanes. This agent utilizes albumin pathways to achieve enhanced and targeted drug delivery to the tumour. The lack of solvent also means that it is well tolerated, despite the lack of premedications. Paclitaxel albumin is licensed in the United States and Europe as >= 2nd-line therapy in MBC (260 mg/m(2) once every three weeks), but emerging evidence suggests it has activity in various settings as weekly therapy and in combination with other agents. Additional strategies to optimize taxane-based therapy are also being evaluated, including the possibility of tailoring treatment according to patient/disease characteristics, identifying predictive biomarkers and evaluating other novel taxanes. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据